Phase 2 trial of chronic low-dose oral etoposide as salvage therapy of platinum-refractory ovarian cancer

Maurie Markman, Thomas Hakes, Bonnie Reichman, John Curtin, Richard Barakat, Stephen Rubin, Walter Jones, John L. Lewis, Lois Almadrones, William Hoskins

Research output: Contribution to journalArticlepeer-review

57 Scopus citations

Abstract

Eighteen previously treated patients with advanced ovarian cancer were entered into a phase 2 trial of chronic low-dose oral etoposide (50 mg/day for 20 days, repeated every 28 days) to determine the activity of this therapeutic strategy in organoplatinum-refractory disease. The treatment program was generally well tolerated, with mild neutropenia the most common side-effect encountered. One patient (6%; 95% confidence interval=0-17%) achieved a partial response, which lasted for 11 months. Three additional patients (17%), who failed to meet the criteria of a partial response, demonstrated objective evidence of antineoplastic activity. Chronic low-dose oral etoposide administration is associated with definite, although modest, activity in platinumrefractory ovarian cancer.

Original languageEnglish
Pages (from-to)55-57
Number of pages3
JournalJournal of Cancer Research and Clinical Oncology
Volume119
Issue number1
DOIs
StatePublished - Jan 1992

Keywords

  • Cancer chemo
  • Etoposide
  • Ovarian cancer
  • therapy

Fingerprint

Dive into the research topics of 'Phase 2 trial of chronic low-dose oral etoposide as salvage therapy of platinum-refractory ovarian cancer'. Together they form a unique fingerprint.

Cite this